OR WAIT null SECS
August 09, 2022
The European Commission has approved AstraZeneca and Merck’s Lynparza (olaparib) as an adjuvant treatment for BRCA-mutated HER2-negative high-risk early breast cancer.
August 05, 2022
The OMNI Electric Utility Raceway power and data management system is designed to reduce risk and accelerate cleanroom delivery.
La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.
August 04, 2022
Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.
Better clinical data are needed, as well as strategies for tackling opioid abuse, tobacco use, and food safety.
August 03, 2022
Ipsen and Marengo Therapeutics will collaborate to advance two precision immuno-oncology candidates.
August 02, 2022
CRYOPDP is expanding its footprint to Spain with its acquisition of Polar Expres.
Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.
The new facility in Albany, Ore., will support biopharmaceutical development and lyophilization services.
Novasep-PharmaZell will increase API production capacity at its Mourenx site with €7.3M investment.